6
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T20365 |
Monopotassium glutamate
L-谷氨酸钾盐,Potassium glutamate,Potassium L-glutamate |
Others | Others |
Monopotassium glutamate (Potassium glutamate) 可在食品中用作增味剂。 | |||
T6504 |
Flupirtine maleate
Katadolon maleate,氟吡啶马来酸,马来酸氟吡汀 |
Potassium Channel; NMDAR; iGluR | Membrane transporter/Ion channel; Neuroscience |
Flupirtine maleate (Katadolon maleate) 是可透过血脑屏障的、具有口服活性的非阿片类化合物。它是间接 NMDAR 拮抗剂,可用于缓解疼痛的研究,具有神经保护特性。 | |||
T0030 |
Bupivacaine hydrochloride
Vivacaine,Bupivacaine HCl,盐酸布比卡因 |
Sodium Channel | Membrane transporter/Ion channel |
Bupivacaine hydrochloride (Vivacaine) 是NMDA 受体抑制剂,可用于慢性疼痛的研究。它可阻断钠、L-钙和钾通道,还阻断SCN5A 通道,IC50为 69.5 μM。 | |||
T0675 |
Topiramate
RWJ 17021,McN 4853,托吡酯 |
Potassium Channel; Calcium Channel; GABA Receptor; Sodium Channel; GluR; Carbonic Anhydrase; iGluR | Membrane transporter/Ion channel; Metabolism; Neuroscience |
Topiramate (RWJ 17021) 是一种GluR5受体拮抗剂,可通过增强GABAergic 活性,抑制kainate/AMPA 受体,抑制钠和钙通道的电压敏感,增加钾电导并抑制碳酸酐酶来产生抗癫痫作用,用于治疗部分性和全身性癫痫发作。 | |||
T36482 |
Lamotrigine isethionate
|
||
Water-soluble salt of lamotrigine . Displays anticonvulsant effects and inhibits glutamate release, possibly through inhibition of Na+, K+ and Ca2+ currents. Leach et al (1991) Neurochemical and behavioral aspects of lamotr. Epilepsia 32 S4 PMID:1685439 |Smith and Meldrum (1995) Cardioprotective effect of lamotr. after focal ischemia in rats. Stroke 26 117 PMID:7839380 |Zona and Avoli (1997) Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38 522 PMI... | |||
T75793 |
ω-Agatoxin IVA TFA
|
||
ω-Agatoxin IVA TFA 是一种高效的针对P/Q型Ca2+(Cav2.1)通道的选择性阻滞剂,IC50对P型为2 nM,对Q型为90 nM。此化合物能够抑制高钾条件下的谷氨酸释放和钙流入,IC50在30-225 nM范围。同时,ω-Agatoxin IVA TFA阻断高钾诱发的5-羟色胺及去甲肾上腺素释放,但不影响L型或N型Ca2+通道。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1186 |
Ifenprodil Tartrate
|
Potassium Channel; NMDAR; iGluR | Membrane transporter/Ion channel; Neuroscience |
Ifenprodil tartrate 是典型的非竞争性 NMDA 受体拮抗剂,抑制 GIRK (Kir3),通过基底 GIRK 活性减少内向电流,有用做脑血管舒张试剂的潜力。它对 NR1A/NR2B 受体亲和力是 NR1A/NR2A 受体的 400 倍。 |